Canadian Partnership for Research in Immunotherapy Manufacturing Excellence (CanPRIME)

Cancer remains the leading causes of mortality worldwide. While treatments are available, existing chemotherapies and radiation therapy have limited success due to secondary effects on healthy cells, resulting in adverse side effects in patients. Over the past 5 years, we have witnessed the development of new and promising cancer therapeutics that stimulate and awaken the body’s immune system to attack tumor cells. These new biologically-based therapies, known as immunotherapeutics, have already begun to show great promise in a number of clinical trials. Among immunotherapeutics, Oncolytic Viruses (OV), also known as cancer killing viruses, are at the forefront. In the lab, we discovered a new viral platform named “SKV” that has the ability to safely target and kill a number of different tumor cells types, while successfully activating the immune system against tumor tissues. TO BE CONT’D

Faculty Supervisor:

Carolina Ilkow;Kevin S. Holmes;Jean-Simon Diallo

Student:

Partner:

Turnstone Biologics

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Algonquin College; Algonquin College of Applied Arts and Technology; University of Ottawa

Program: